InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Accardi Mario Alberto, President, Orexin Program. Insider active across 1 company, notably Centessa Pharmaceuticals plc. Cumulatively, 14 disclosures have been logged. Breakdown: 0 buy · 5 sells. Total volume traded: €505k. Activity tracked since 24 June 2025. The latest transaction was filed on 1 February 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Accardi Mario Alberto
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
243,282 sharesOrdinary SharesSEC:0001470831-26-000616:0
2,915 shares@ US$24.579.9% of flowOrdinary SharesSEC:0001470831-26-000088:0
68,000 shares0Ordinary SharesSEC:0001470831-26-000088:1
7,432 shares@ US$28.69830.3% of flowOrdinary SharesSEC:0001470831-25-000390:0
2,568 shares@ US$29.207710.6% of flowOrdinary SharesSEC:0001470831-25-000390:1
5,000 shares@ US$9.530.0007% mcap27.2% of flowOrdinary SharesSEC:0001470831-25-000388:0
593 shares@ US$24.901.7% of flowOrdinary SharesSEC:0001470831-25-000288:0
5,000 shares@ US$8.010.0006% mcap22.8% of flowOrdinary SharesSEC:0001470831-25-000273:0
7,430 shares@ US$21.333322.1% of flowOrdinary SharesSEC:0001470831-25-000208:0
742 shares@ US$22.02132.3% of flowOrdinary SharesSEC:0001470831-25-000208:1
5,000 shares@ US$8.014.7% of flowOrdinary SharesSEC:0001470831-25-000187:0
597 shares@ US$17.171.3% of flowOrdinary SharesSEC:0001847903-25-000127:0
8,322 shares@ US$15.230815.7% of flowOrdinary SharesSEC:0001847903-25-000125:0
15,000 shares@ US$3.858.6% of flowOrdinary SharesSEC:0001847903-25-000113:0
14 of 14 declarations
About Accardi Mario Alberto
Mario Alberto Accardi is the President of the Orexin Program at Centessa Pharmaceuticals plc. In this role, he is responsible for the strategic and operational direction of the program, aiming to develop innovative treatments. His expertise in the pharmaceutical field is essential for advancing the company's goals and improving patient outcomes.
